Averill Partners, a biopharma-focused long-short hedge fund, will stop accepting new investments starting November 1, having achieved a remarkable 385.8% return since its launch in early 2020. The fund, led by Kishen Mehta, has excelled through strategic short selling and currently manages $1.7 billion in assets. Averill Madison, a separate health care fund, remains open to new capital.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
